Profile data is unavailable for this security.
About the company
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets, and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs. The Company develops and in-licenses products for sale by sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. Its products include A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Candaderm, Coco-Scalp, Cromo-Fresh, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE, Itch-Soothe, Kiwisoothe, Lax-Tab, Loraclear, VitA-POS, and others.
- Revenue in NZD (TTM)236.25m
- Net income in NZD17.45m
- Incorporated1997
- Employees119.00
- LocationAFT Pharmaceuticals LtdLevel 1, 129 Hurstmere RoadAUCKLAND 0622New ZealandNZL
- Phone+64 94880232
- Fax+64 94880234
- Websitehttps://www.aftpharm.com/
Mergers & acquisitions
| Acquired company | AFT:NZC since announced | Transaction value |
|---|---|---|
| Pharma Dynamics (Pty) Ltd-Hospital Division Business | -0.28% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dawnrays Pharmaceutical (Holdings) Ltd | 267.11m | 42.34m | 375.85m | 1.12k | 8.89 | 0.4741 | 6.00 | 1.41 | 0.1327 | 0.1327 | 0.8371 | 2.49 | 0.2809 | 2.47 | 7.96 | 1,065,846.00 | 4.36 | 10.98 | 5.07 | 13.75 | 45.76 | 55.52 | 15.53 | 32.76 | 4.21 | -- | 0.0028 | 31.01 | -7.89 | 2.22 | 73.29 | 17.20 | 17.13 | 2.69 |
| Morepen Laboratories Ltd | 326.72m | 18.18m | 386.24m | 1.81k | 21.24 | -- | 14.33 | 1.18 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| AFT Pharmaceuticals Ltd | 236.25m | 17.45m | 389.96m | 119.00 | 22.24 | 3.91 | 19.57 | 1.65 | 0.1664 | 0.1664 | 2.25 | 0.9452 | 1.48 | 2.48 | 7.28 | 1,985,294.00 | 10.38 | 9.68 | 15.19 | 13.24 | 44.53 | 45.24 | 7.02 | 8.13 | 0.6944 | 9.01 | 0.2788 | 7.31 | 6.45 | 14.52 | -23.36 | 0.4473 | 1.16 | -- |
| Panacea Biotec Ltd | 110.41m | -1.32m | 392.04m | 1.29k | -- | 2.59 | 81.72 | 3.55 | -1.18 | -1.18 | 98.44 | 134.92 | 0.4836 | 1.38 | 8.67 | 4,681,039.00 | -0.6085 | 13.08 | -0.8291 | 19.61 | 58.47 | 48.06 | -1.26 | 30.99 | 0.9785 | -14.33 | 0.0271 | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| Cutia Therapeutics | 60.06m | -113.31m | 396.44m | 298.00 | -- | 1.93 | -- | 6.60 | -1.70 | -1.70 | 0.9023 | 2.67 | 0.1908 | 2.55 | 5.57 | 851,414.80 | -36.00 | -- | -44.42 | -- | 34.92 | -- | -188.66 | -- | 2.92 | -- | 0.2774 | -- | 103.17 | -- | 77.91 | -- | -- | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 301.15m | 17.43m | 401.13m | 2.89k | 23.00 | -- | 14.27 | 1.33 | 3.25 | 3.25 | -- | -- | -- | -- | -- | 5,696,991.00 | -- | 10.26 | -- | 13.42 | 34.43 | 32.57 | 5.79 | 9.33 | -- | 8.05 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Zhaoke Ophthalmology Ltd | 8.48m | -66.78m | 401.65m | 270.00 | -- | 0.9779 | -- | 47.34 | -0.5698 | -0.5698 | 0.0725 | 3.54 | 0.0159 | 1.38 | 9.25 | 136,211.20 | -12.50 | -38.02 | -14.65 | -41.79 | 49.28 | -- | -787.13 | -4,412.89 | 4.36 | -29.83 | 0.1373 | -- | 269.73 | -- | 38.32 | -- | 18.80 | -- |
| Solara Active Pharma Sciences Ltd | 229.42m | -3.49m | 403.66m | 1.78k | -- | -- | 28.01 | 1.76 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Accident Compensation Corp.as of 30 Apr 2025 | 7.50m | 7.15% |
| Guardians of New Zealand Superannuationas of 30 Jun 2025 | 1.69m | 1.61% |
| Pengana Capital Ltd.as of 31 Oct 2025 | 1.02m | 0.98% |
| Salt Funds Management Ltd.as of 30 Apr 2025 | 768.12k | 0.73% |
| Kernel Wealth Ltd.as of 31 Jan 2026 | 97.33k | 0.09% |
| FCA Corp.as of 31 Dec 2025 | 46.00k | 0.04% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 35.59k | 0.03% |
